The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of higher initial dose and accelerated titration of ropeginterferon alfa-2b on early hematologic and molecular responses in polycythemia vera: A meta-analysis.
 
Abdulraheem Yacoub
Consulting or Advisory Role - Abbvie; Blueprint Pharmaceutic; Geron; GlaxoSmithKline; Incyte; Karyopharm Therapeutics; Novartis; SERVIER; SOBI
Research Funding - SOBI; Stemline Therapeutics
 
Shinya Imada
Employment - Microbial Machines; PharmaEssentia
 
Chun-Ting Wu
Employment - PharmaEssentia
 
Shaoyu Chang
Employment - PharmaEssentia
Stock and Other Ownership Interests - Vertex
 
Charles Edward Jefford
Employment - PharmaEssentia
 
Kyle Downey
Employment - Genentech; PharmaEssentia
Stock and Other Ownership Interests - Roche; Sanofi
 
Harvey Chin
Employment - PharmaEssentia
 
Albert Qin
Employment - PharmaEssentia
Leadership - PharmaEssentia
Stock and Other Ownership Interests - PharmaEssentia
 
Anthony Hunter
Honoraria - Blueprint Medicines; Pharmaessentia; Sobi
Consulting or Advisory Role - Blueprint Medicines; Bristol-Myers Squibb/Celgene; Cycle Therapeutics; Geron; GlaxoSmithKline; Incyte; Novartis; Pharmaessentia; Refined Oncology; SOBI
Research Funding - Ascentage Pharma (Inst); Blueprint Medicines (Inst); Cogent Biosciences (Inst); Disc Medicine (Inst); Incyte (Inst); Novartis (Inst); Pharmaessentia (Inst); Shenzen TargetRx (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Syntrix Biosystems (Inst); Telios (Inst)